KRAS mutations occur in ~15-25% of endometrioid endometrial cancers; G12C is a minority s...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-KRAS-G12C-ENDOMETRIAL |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-ENDOMETRIAL |
| Sources | SRC-CIVIC SRC-NCCN-UTERINE-2025 |
Actionability Facts
| Biomarker | BIO-KRAS-G12C |
|---|---|
| Variant | G12C |
| Disease | DIS-ENDOMETRIAL |
| ESCAT tier | IIIA |
| Recommended combinations | sotorasib (off-label), adagrasib (off-label) |
| Evidence summary | KRAS mutations occur in ~15-25% of endometrioid endometrial cancers; G12C is a minority subset. Tissue-agnostic rationale with sotorasib/adagrasib supported by NCCN as off-label option in pretreated G12C+ disease. |
Notes
ESCAT IIIA. Limited prospective endometrial-specific data.
Used By
No reverse references found in the YAML corpus.